Therapeutic equivalence of ursodeoxycholic acid tablets and ursodeoxycholic acid capsules for the treatment of primary biliary cirrhosis

摘要

Primary biliary cirrhosis (PBC) is a chronic cholestatic, progressive inflammatory liver disease with a suspected autoimmunological pathogenesis.[1] The disease is typically diagnosed in women at an age between 30 and 65 years and has a prevalence of up to 1 in 1000 women over the age of 40.[2] The only approved medical therapy for PBC is ursodeoxycholic acid (UDCA) in a recommended dose of 13–15?mg/kg/day.[3]